$5.81
(Market cap
$9,663 Mln
Revenue (TTM)
$440 Mln
P/E Ratio
41
P/B Ratio
7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
42.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$8
-
Face value
--
-
Shares outstanding
29,598,836
8 Years Aggregate
CFO
$-296.75 Mln
EBITDA
$-338.60 Mln
Net Profit
$-269.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
| 35.0 | -9.0 | 6.4 | 142.0 | 40.9 | 42.2 | -- |
|
BSE Sensex*
| -7.9 | 0.6 | 4.6 | -2.8 | 6.1 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
| 57.4 | 26.0 | 56.6 | 13.3 | 16.6 | 8.3 | 166.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Krystal Biotech (KRYS)
|
332.9 | 9,662.5 | 440.5 | 241.5 | 33.4 | 18.7 | 41 | 7.0 |
| 87.3 | 12,381.0 | 669.5 | -320.0 | -0.8 | -68.2 | -- | 26.6 | |
| 84.5 | 8,920.5 | 42.2 | -501.6 | -1,217.0 | -45.9 | -- | 6.9 | |
| 75.6 | 10,421.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 50.4 | 13,397.6 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 101.8 | 12,231.4 | 1,663.7 | 413.6 | 18.8 | 430 | 36.2 | 45.0 | |
| 536.2 | 11,784.0 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.7 | |
| 597.0 | 16,486.6 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.4 | 37.6 | |
| 386.3 | 10,057.6 | 0.0 | -339.1 | -- | -30.6 | -- | 6.1 | |
| 152.0 | 9,439.0 | 282.0 | 82.9 | -28.6 | 11.4 | 143 | 11.2 |
Shareholding Pattern
View DetailsAbout Krystal Biotech (KRYS)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK... (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Read more
-
Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
-
Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
-
Headquarters
Pittsburgh, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Krystal Biotech (KRYS)
What is the current share price of Krystal Biotech Inc (KRYS) Today?
The share price of Krystal Biotech Inc (KRYS) is $332.86 (NASDAQ) as of 12-Aug-2026 16:00 EDT. Krystal Biotech Inc (KRYS) has given a return of 40.92% in the last 3 years.
What is the current PB & PE ratio of Krystal Biotech Inc (KRYS)?
The P/E ratio of Krystal Biotech Inc (KRYS) is 40.96 times as on 07-Aug-2026.
The P/B ratio of Krystal Biotech Inc (KRYS) is 7.03 times as on 07-Aug-2026, a 32 premium to its peers’ median range of 5.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
36.05
|
6.05
|
|
2024
|
52.51
|
4.95
|
|
2023
|
327.03
|
4.59
|
|
2022
|
-14.46
|
3.88
|
|
2021
|
-22.33
|
2.62
|
What is the 52 Week High and Low of Krystal Biotech Inc (KRYS)?
The 52-week high and low of Krystal Biotech Inc (KRYS) are Rs 382.54 and Rs 136.73 as of 13-Aug-2026.
What is the market cap of Krystal Biotech Inc (KRYS)?
Krystal Biotech Inc (KRYS) has a market capitalisation of $ 9,663 Mln as on 07-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Krystal Biotech Inc (KRYS)?
Before investing in Krystal Biotech Inc (KRYS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.